Optas LLC Purchases 2,043 Shares of Pfizer Inc. (NYSE:PFE)

Optas LLC increased its position in Pfizer Inc. (NYSE:PFEFree Report) by 25.5% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 10,044 shares of the biopharmaceutical company’s stock after acquiring an additional 2,043 shares during the period. Optas LLC’s holdings in Pfizer were worth $279,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of the company. Chatham Capital Group Inc. grew its holdings in shares of Pfizer by 4.1% in the first quarter. Chatham Capital Group Inc. now owns 31,594 shares of the biopharmaceutical company’s stock worth $877,000 after acquiring an additional 1,237 shares during the period. Red Door Wealth Management LLC grew its holdings in Pfizer by 1.9% during the first quarter. Red Door Wealth Management LLC now owns 144,804 shares of the biopharmaceutical company’s stock valued at $4,018,000 after purchasing an additional 2,674 shares during the period. Gradient Capital Advisors LLC grew its holdings in Pfizer by 30.1% during the first quarter. Gradient Capital Advisors LLC now owns 22,353 shares of the biopharmaceutical company’s stock valued at $620,000 after purchasing an additional 5,171 shares during the period. Cornerstone Wealth Group LLC grew its holdings in Pfizer by 72.0% during the first quarter. Cornerstone Wealth Group LLC now owns 15,412 shares of the biopharmaceutical company’s stock valued at $428,000 after purchasing an additional 6,452 shares during the period. Finally, New Mexico Educational Retirement Board grew its holdings in Pfizer by 11.1% during the first quarter. New Mexico Educational Retirement Board now owns 326,400 shares of the biopharmaceutical company’s stock valued at $9,058,000 after purchasing an additional 32,700 shares during the period. Institutional investors own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have issued reports on the company. BMO Capital Markets reissued an “outperform” rating and set a $36.00 price target (up previously from $33.00) on shares of Pfizer in a report on Thursday, May 2nd. Morgan Stanley boosted their price target on Pfizer from $28.00 to $29.00 and gave the company an “equal weight” rating in a report on Thursday, May 2nd. Cantor Fitzgerald reissued an “overweight” rating and set a $45.00 price target on shares of Pfizer in a report on Wednesday, June 26th. Finally, Argus downgraded Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Nine equities research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $35.54.

View Our Latest Research Report on Pfizer

Pfizer Trading Up 0.6 %

Shares of PFE stock opened at $27.98 on Monday. Pfizer Inc. has a 1 year low of $25.20 and a 1 year high of $37.80. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.05 and a quick ratio of 0.78. The stock’s 50 day simple moving average is $27.90 and its two-hundred day simple moving average is $27.69. The company has a market cap of $158.55 billion, a PE ratio of -466.26, a price-to-earnings-growth ratio of 1.10 and a beta of 0.69.

Pfizer (NYSE:PFEGet Free Report) last issued its quarterly earnings data on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.56 by $0.26. Pfizer had a positive return on equity of 8.64% and a negative net margin of 0.56%. The business had revenue of $14.88 billion for the quarter, compared to the consensus estimate of $13.87 billion. During the same period in the prior year, the business posted $1.23 earnings per share. The company’s quarterly revenue was down 19.5% compared to the same quarter last year. Research analysts predict that Pfizer Inc. will post 2.38 earnings per share for the current year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 3rd. Stockholders of record on Friday, July 26th will be paid a dividend of $0.42 per share. The ex-dividend date of this dividend is Thursday, July 25th. This represents a $1.68 dividend on an annualized basis and a dividend yield of 6.00%. Pfizer’s dividend payout ratio is -2,799.53%.

Pfizer Company Profile

(Free Report)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Further Reading

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFEFree Report).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.